Board and Management

Underpinned by leading management, extensive experience and industry validation.

Proven Industry Expertise

Commercialisation Experience

Strategic Leadership

MANAGEMENT TEAM

Dr Danielle Meyrick

Chief Executive Officer

Dr Meyrick has over 20 years’ experience across clinical development, radiopharmaceuticals and isotope-based technologies.

A proven track record in senior leadership roles at Telix Pharmaceuticals (ASX: TLX), ITM Isotopes and GenesisCare CRO, directly supporting near term progression of Stabl-Im.
Kai Sun

Chief Operating Officer

Mr Sun drives the company’s mission to innovate the connection between biological markers and mental health conditions.

Previously, he scaled one of the largest corporate health and fitness platforms in Australia and holds a Bachelors of Laws and Commerce from the University of Western Australia.

Board of Directors

David Trimboli

Non-executive Chairman

Mr Trimboli is an experienced global investor with experience in commodities financing and trading. He has undertaken investment activities and holds diverse interests in commodities including technology and mental health in Australia and internationally.

He currently holds a Managing Director position in Seefeld Investments Pty Ltd, Non-Executive Chairman in Audeara Limited (ASX: AUA) and Non-Executive Director positions in the following Companies Quantum Graphite Limited (ASX: QGL), TradeMutt, Yumm Confectionar, The Reading Switch, Carecircle and Greater Outcomes.
Dr Tony Keating

Executive Director

Dr Keating was the co-founder and Chief Executive Officer of ResApp Health, a digital health company which developed a groundbreaking smartphone technology for accurately diagnosing respiratory diseases based on cough analysis.

Dr Keating led the ResApp team through the commercialisation of the company’s technology, commencing with a successful R&D phase through to global regulatory approvals and commercial partnerships, before overseeing the sale of the company to Pfizer in 2022 for $180m. Following the acquisition, he transitioned to Vice President at Pfizer.
Chris Ntoumenopoulos

Non-executive Director

Mr Ntoumenopoulos holds the position as a Director at Tryp Therapeutics. He has a background as the former Managing Director at 21 Corporate, an Australian corporate advisory firm. He is also a seasoned entrepreneur actively on the lookout for innovative and groundbreaking technologies and businesses.

With over 20 years of experience in the financial sector, Mr Ntoumenopoulos has a strong track record in raising capital and providing strategic corporate advice to companies. He was also a founding director of ResApp Health, which Pfizer and Race Oncology later acquired.

Scientific Advisory

Dr Daniel Tillett

Scientific Advisor

Dr Daniel Tillett is a highly-regarded biotechnology entrepreneur, investor and innovator with more than 25 years’ experience in molecular biology, genomics, and commercial biotech development.

Alongside his role with TrivarX, he is also CEO and Managing Director of Race Oncology Limited (ASX: RAC) – one of Australia’s leading precision oncology companies.